Abstract: A series circuit includes a capacitor connected in series with output terminals of a power converter. The power converter provides an auxiliary voltage and a controller controls the auxiliary voltage according to a selected function, such that the series circuit behaves as a capacitor, an inductor, or an impedance, based on the selected function. The controller may sense a voltage across the capacitor and use the sensed voltage to control the auxiliary voltage according to the selected function. The series circuit may be connected in parallel with output terminals of an AC-DC converter, wherein the series circuit operates according to a selected mode to produce the auxiliary voltage, and the auxiliary voltage substantially cancels a low frequency AC voltage ripple across the capacitor, such that a substantially pure DC output voltage is delivered to the load.

Abstract: Resonant converters with wide voltage gain ranges are achieved by controlling at least one of the primary side resonant circuit and the secondary side rectifier circuit. A switch is included in at least one of the primary or secondary sides, and control of the switch according to a selected mode determines an output voltage of the resonant converter. Embodiments accommodate wide input and output voltage ranges, and are suitable for use in AC-DC power adapters for portable devices with different voltage requirements, such as cell phones, tablets, and notebook computers, as well as in DC-DC converter applications including electric vehicle power systems.

Abstract: The present application provides stable, carbene-functionalized composite materials, and methods and uses thereof. These carbene-functionalized composite materials comprise a material having a metal surface, and a carbene monolayer that is uniform, contaminant-free (metal oxide, etc), and more stable than thiol-functionalized monolayers. Uses of such carbene-functionalized composite materials include semi-conducting materials, microelectronic devices, drug delivery or sensing applications.

Abstract: A class of compounds useful in pharmaceutical compositions and methods for treating or preventing cancer is described. Analogs of Mycalolide B have been prepared and tested in breast and ovarian cancer cell lines. The compounds show utility for inhibition of survival and proliferation of tumor cells. The compounds have been shown to disrupt actin.

Abstract: Compounds described herein are inhibitors of retinoic add inducible P450 (CYP26) enzymes, and are useful for treating diseases that are responsive to retinoids. Certain compounds have retinoid activity, are resistant to CYP26-mediated catabolism, and are used for treating diseases that are responsive to retinoids.

Abstract: Compounds that are inhibitors of retinoic acid inducible P450 (CYP26) enzymes. The compounds have retinoid activity, are resistant to CYP26-mediated catabolism, act as inhibitors of CYP26B1, and are used for treating diseases that are responsive to retinoids.

Abstract: The present disclosure provides methods of making nicotinoyl riboside compounds or derivatives of formula (I): wherein X?, Z1, Z2, n, R1, R2, R3, R4, R5, R6, R7, and R8 are described herein, reduced analogs thereof, modified derivatives thereof, phosphorylated analogs thereof, and adenylyl dinucleotide conjugates thereof, or salts, solvates, or prodrugs thereof; and novel crystalline forms thereof.

Abstract: A start-up circuit for a power converter includes a charging circuit that uses a DC bus voltage of the power converter to generate a charging current to charge an energy storage device to a selected voltage and an auxiliary power output circuit including a transformer primary side auxiliary winding. A control circuit controls one or more switches of the start-up circuit and one or more switches of the power converter primary side. The charging current provides power to the control circuit until the auxiliary power is established. The control circuit disables the start-up circuit when the auxiliary power output is established. The start-up circuit has very low standby power consumption and compact size, and is particularly suitable for power converter applications such as power adapters for portable electronic devices.

Abstract: A method for detecting long QT syndrome in a subject comprises obtaining data corresponding to an electrocardiogram (ECG) signal of the subject, identifying a set of features in the data based on selected inflection points of the ECG signal, using the set of features to categorize segments of the ECG signal, and using the categorized segments of the ECG signal and the inflection points to classify the ECG signal as normal or as long QT syndrome. Long QT syndrome is detected when the subject's ECG signal is classified as long QT syndrome. The method may include determining whether the long QT syndrome is Type 1 or Type 2.

Abstract: The present disclosure provides methods of making nicotinoyl riboside compounds or derivatives of formula (I): wherein X?, Z1, Z2, n, R1, R2, R3, R4, R5, R6, R7, and R8 are described herein, reduced analogs thereof, modified derivatives thereof, phosphorylated analogs thereof, and adenylyl dinucleotide conjugates thereof, or salts, solvates, or prodrugs thereof; and novel crystalline forms thereof.

Abstract: Study of intracardiac electrograms (IEGMs) during atrial fibrillation (AF) provides clinically significant information that can be used in ablation therapy. Methods include determining a regional feature, e.g., dominant frequency (RDF), which encompasses the relationship between simultaneously recorded electrodes and identifies the feature components of a region, rather than the feature of a single electrode. Methods employing the regional feature may be used to identify and characterize variation and disorganization in wavefront propagation or wave breaks (WBs) at each recording site, and may be used to direct catheter ablation therapy.

Abstract: The present disclosure provides methods of making nicotinoyl riboside compounds or derivatives of formula (I): wherein X?, Z1, Z2, n, R1, R2, R3, R4, R5, R6, R7, and R8 are described herein, reduced analogs thereof, modified derivatives thereof, phosphorylated analogs thereof, and adenylyl dinucleotide conjugates thereof, or salts, solvates, or prodrugs thereof; and novel crystalline forms thereof.

Abstract: The present disclosure provides methods of making nicotinoyl riboside compounds or derivatives of formula (I): wherein X?, Z1, Z2, n, R1, R2, R3, R4, R5, R6, R7, and R8 are described herein, reduced analogs thereof, modified derivatives thereof, phosphorylated analogs thereof, and adenylyl dinucleotide conjugates thereof, or salts, solvates, or prodrugs thereof, and novel crystalline forms thereof.

Abstract: The present application provides switchable, homogeneous paint composition and methods of painting and/or forming films or coatings using the composition. The composition includes a liquid having an aqueous solution and dissolved acid gas (e.g., carbonated water), and a switchable polymer. The switchable polymer converts from a protonated, water-soluble form in the liquid to a water-insoluble unprotonated form following removal or substantial removal of the liquid and acid gas.

Abstract: A surface enhanced Raman spectroscopy (SERS) device, comprises a non-electrically conductive substrate, at least two microelectrodes disposed on the substrate in a spaced relationship such that a detection site is formed along edges and/or between opposing edges of the microelectrodes, and a nanoparticle structure comprising a plurality of metallic nanoparticles disposed in the detection site. Assembly of the nanoparticle structure may be directed by an electric field between the at least two microelectrodes. The SERS device is inexpensive, robust, portable, and reusable. Also described herein are methods for using and preparing the SERS devices with simple, rapid, and inexpensive fabrication techniques.

Abstract: Pharmaceutical compositions that include inhibitors of mitochondrial fission are described for the treatment and/or mitigation of cancer, pulmonary arterial hypertension, cardioprotection, stroke, coronary heart disease, neurological disorder, a neurodegenerative disease, Parksinonism, Huntington's Chorea, Alzheimer's disease, diabetic cardiomyopathy, fatty liver diseases, non-alcoholic fatty liver diseases, or alcohol-related liver disease.

Abstract: Provided are apparatus and methods for generating a representation of a physical environment, comprising: a mobile sensor platform (MSP) including sensors that output sensor signals relating to parameters such as range, gravity, direction of the Earth's magnetic field, and angular velocity. The MSP is adapted to be moved through the environment. The sensor signals are processed and observations of axes in the environment are generated for a sequence of time steps, the orientation of the MSP is estimated for each of the time steps, observed axes are identified at each orientation, and similar axes are associated. The orientations, the axes in the environment, and the directions of gravity and the Earth's magnetic field are linked such that each observation is predicted based on the estimates of the orientations. An estimate of the orientations is optimized and an output of the representation of the physical environment is generated based on the optimized orientation estimates.

Abstract: The invention provides liquid injectable copolymers of TMC and HTMC that are degradable in vivo. Degradation can be tailored by adjusting the amount of HTMC in the copolymer, the initial molecular weight of the copolymer, and the characteristics of the initiator used in its preparation. Specifically, the degradation rate increases as the amount of HTMC incorporated into the copolymer increases, as the molecular weight of the copolymer decreases, and as the hydrophobicity of the initiator decreases. Moreover, the degradation yields products such as glycerol and carbon dioxide that are non-toxic in vivo, and which will not cause a substantive change in tissue pH upon implantation in vivo. The copolymers may be used in applications such as drug delivery and as coatings.

Abstract: The present disclosure provides methods of making nicotinoyl riboside compounds or derivatives of formula (I): wherein X?, Z1, Z2, n, R1, R2, R3, R4, R5, R6, R7, and R8 are described herein, reduced analogs thereof, modified derivatives thereof, phosphorylated analogs thereof, and adenylyl dinucleotide conjugates thereof, or salts, solvates, or prodrugs thereof; and novel crystalline forms thereof.

Abstract: The present disclosure provides methods of making nicotinoyl riboside compounds or derivatives of formula (I): wherein X?, Z1, Z2, n, R1, R2, R3, R4, R5, R6, R7, and R8 are described herein, reduced analogs thereof, modified derivatives thereof, phosphorylated analogs thereof, and adenylyl dinucleotide conjugates thereof, or salts, solvates, or prodrugs thereof; and novel crystalline forms thereof.